Human Serum vs. hPL vs. FBS — Which Supplement for MSC and ATMP Manufacturing?
Three supplements, three different problems solved. This comparison covers what each one does well, where each fails, and what a switch actually costs you in validation time.
What each one actually is
FBS — Fetal Bovine Serum
Bovine origin, collected from foetal calf blood. Rich in growth factors, low in immunoglobulins, and the reference supplement for cell culture for over fifty years. Xenogeneic by definition.
HS — Human Serum
From human whole blood or plasma. Removes the species barrier. Type AB avoids isoagglutinins; off-the-clot preserves the platelet growth factor profile.
hPL — Human Platelet Lysate
Produced by lysing platelet concentrates, usually through freeze-thaw cycles. The α-granules rupture and release their contents, giving a supplement far richer in growth factors than either serum.
Side by side
| FBS | Human Serum (AB) | hPL | |
|---|---|---|---|
| Origin | Bovine — xenogeneic | Human | Human |
| Growth factor content | Moderate to high | Moderate | High |
| MSC proliferation | Reference | Comparable to slower | Markedly faster |
| Xeno-free claim | No | Yes | Yes, if heparin-free |
| ATMP acceptance | Under regulatory pressure | Accepted | Established practice |
| Handling issues | None specific | None specific | Fibrinogen — gel formation |
| Batch variability | High, seasonal and regional | Donor dependent | Reduced by large pools |
| Typical use level | 10 % | 5–10 % | Often 5 % or less |
| Supply | Volatile, price sensitive | Limited, especially AB off-the-clot | Good |
| Ethical profile | Contested — 3Rs pressure | Donor consent based | Uses expired platelet units |
Why FBS is losing ground in clinical work
Not because it performs badly. Because it is bovine.
Four arguments come up in every ATMP review, and none of them is about culture performance:
- Immunogenicity. Cells cultured in FBS internalise bovine proteins. When those cells are administered to a patient, the bovine material comes with them. Immune responses to bovine serum albumin have been documented in cell therapy recipients.
- Adventitious agents. TSE and viral risk is managed through sourcing and testing, but it cannot be eliminated by design the way it can with a human-origin product.
- Batch variability. Composition varies with herd, region and season. For a process that must stay comparable over years, that is a validation burden rather than a nuisance.
- Supply and price. The FBS market has repeatedly shown sharp price movements and constrained availability. A clinical programme cannot absorb that.
For research on established cell lines none of this applies with force, and FBS remains the pragmatic choice. Our FBS origin comparison covers the sourcing question separately.
Why hPL outperforms both for MSC
The growth factors are concentrated by design, not by accident.
In serum, platelet growth factors end up in the product as a by-product of clotting — however much the platelets happened to release. In hPL, platelet concentrates are lysed deliberately, so the α-granule contents are the product rather than a residue.
The practical result for mesenchymal stromal cells is faster population doubling, more doublings before senescence, and — importantly for ATMP — retained immunophenotype and differentiation potential. That combination is why hPL has moved from an alternative to the default in clinical MSC manufacturing.
Where human serum is the right answer
Human serum sits between the two, and for several applications that is exactly right.
- Primary human cells that do not need hPL's growth factor intensity but should not see bovine protein
- PBMC and T-cell work — Type AB is the established standard, and hPL's proliferative push is not always wanted here
- Physiological modelling — human serum is a human matrix; hPL is a concentrate and represents no physiological state
- Hormone-sensitive systems, where male-donor serum gives a controlled profile
- Diagnostic assay development, where you need a representative human background rather than growth factors
There is also a regulatory argument: human serum is a well-understood, long-established material with straightforward donor documentation. For some filings that familiarity is worth more than performance.
What a switch actually costs
None of these is a drop-in replacement. Plan for re-qualification, not a purchase order.
| Switch | What to expect |
|---|---|
| FBS → hPL | Adaptation over several passages. Concentration usually needs lowering — hPL at 10 % is often too much. Heparin or fibrinogen-depleted hPL required. Morphology commonly changes. |
| FBS → human serum | Gentler transition. Growth may slow initially. Off-the-clot Type AB is the closest match to FBS performance. |
| Human serum → hPL | Usually a performance gain, but the same fibrinogen and concentration considerations apply. |
| Any switch, clinical process | Full comparability exercise: identity, potency, differentiation capacity, karyotype stability. Budget months, not weeks. |
We have written up the qualification side separately: switching human serum supplier.
A short decision path
| Your situation | Start with |
|---|---|
| MSC expansion for a clinical or ATMP process | hPL, fibrinogen-depleted |
| MSC expansion, research only | hPL or FBS — hPL if you plan to go clinical later |
| T-cell or CAR-T expansion | Human serum Type AB |
| PBMC and immunology | Human serum Type AB |
| Primary human cells, general | Human serum Type AB, off-the-clot |
| Established immortalised cell lines | FBS |
| Diagnostic assay matrix | Pooled human serum |
| Xeno-free requirement in a filing | hPL heparin-free, or human serum |
Serum-free is the fourth option and a different discussion — see our serum-free adaptation guide and the serum replacement range.
Frequently asked questions
Is hPL always better than FBS?
For mesenchymal stromal cells, generally yes on proliferation. For other cell types the picture is mixed — some lines still perform best in FBS, and hPL's high growth factor content can push cells toward phenotypes you did not intend. Test before committing.
Why does hPL cause gel formation?
It contains fibrinogen from the platelet concentrate. In medium containing calcium, fibrinogen can convert to fibrin. Heparin prevents this, or you use fibrinogen-depleted hPL and avoid the problem entirely.
Is hPL genuinely xeno-free?
The lysate itself is. If your protocol adds porcine heparin to control fibrinogen, the overall process is not. Fibrinogen-depleted, heparin-free hPL is the version to specify when the claim has to hold.
Can I use human serum instead of hPL for MSC?
Yes, and it was the standard before hPL became established. Expect slower proliferation and fewer doublings before senescence. If your process tolerates that, human serum has the simpler documentation trail.
What concentration of hPL should I use?
Usually lower than the FBS concentration you are replacing — often around 5 %, sometimes less. Start with a small concentration series rather than a direct one-to-one substitution; more is not better with hPL.
Does FBS still have a place?
Yes — for established cell lines, routine research and any application with no clinical trajectory. The arguments against it are about origin and regulation, not culture performance.
How does batch variability compare?
FBS varies with herd, region and season. Human serum varies by donor. hPL is typically produced from large donor pools, which averages out individual variation — one of the underrated reasons it suits manufacturing.
Can I get samples of all three?
Yes. For a switch decision, running the three in parallel against your own cells is the only assessment that means anything.
Related
Run all three against your own cells
We supply FBS, human serum and hPL — so we have no reason to talk you into one of them. Tell us the cell type and where the process is heading, and we will send samples of the variants worth testing.
Request samples
English 
Deutsch